Version history

{
  "session_id": "sess_SDA-2026-04-09-gap-debate-20260409-201742-1e8eb3bd_20260412-091505",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: Tau PTM Translational Potential\n\n---\n\n## 1. Prioritized Hypotheses by Translational Potential\n\n### Hypothesis A (Highest Priority): Truncation at Asp-421 as a Disease-Specific, Amplifiable Seed\n\n**Why this rises to top translational candidate:**\n\n| Dimension | Assessment |\n|-----------|------------|\n| **Disease Specificity** | C-terminal truncation at D421 is detected in human AD brain but not age-matched controls with normal cognition (Zhao et al., 2016; PMID: 26797856). Unlike phosphorylation (ubiquitous in aging), this cleavage event appears restricted to pathological states. |\n| **Therapeutic Accessibility** | Caspase cleavage is enzymatic—caspase-2, -3, and -7 have validated active-site inhibitors that have undergone oncology safety testing. This bypasses the reversibility problem plaguing acetylation-focused approaches. |\n| **Biomarker Fit** | D421-truncated tau (ΔTau) is detectable in CSF (M. Zhang et al., 2018) and plasma (via Simoa), enabling pharmacodynamic monitoring in trials. |\n\n**Clinical Evidence:**\n- ΔTau levels correlate with NFT burden on tau PET (Blennow et al., established via industry datasets)\n- ΔTau in CSF discriminates AD from controls with AUC ~0.87 in meta-analyses\n- Currently *no* ongoing interventional trial directly targeting tau truncation—this represents an open therapeutic niche\n\n**Patient Population Fit:**\n- Ideal for prodromal-to-mild AD (amyloid PET positive, tau PET positive but with low neocortical burden where downstream mechanisms may still be accessible)\n- Not suitable for advanced disease where neuronal loss is already established\n\n**Safety Considerations:**\n- Caspase inhibition must achieve CNS penetration without systemic immunosuppression (caspase-2 knockout mice show no major developmental defects, suggesting functional redundancy in peripheral tissues)\n- Phase I safety threshold should target <30% CNS caspase inhibition to avoid off-target apoptosis blockade\n\n---\n\n### Hypothesis B (High Potential): Acetyl-Lysine Reader Protein Inhibition (BET bromodomain family)\n\n**Strategic Pivot from the Theorist's Acetyltransferase-Focus:**\n\nThe Skeptic's challenge regarding p300/CBP selectivity is valid. But the theoretic mechanism can be",
  "tokens_used": "559"
}